CA2287318A1 - Pharmaceutical compositions of arglabin and arglabin derivatives - Google Patents

Pharmaceutical compositions of arglabin and arglabin derivatives Download PDF

Info

Publication number
CA2287318A1
CA2287318A1 CA002287318A CA2287318A CA2287318A1 CA 2287318 A1 CA2287318 A1 CA 2287318A1 CA 002287318 A CA002287318 A CA 002287318A CA 2287318 A CA2287318 A CA 2287318A CA 2287318 A1 CA2287318 A1 CA 2287318A1
Authority
CA
Canada
Prior art keywords
compound
arglabin
composition
treatment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002287318A
Other languages
English (en)
French (fr)
Inventor
Sergazy M. Adekenov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PARACURE Inc DOING BUSINESS AS KAZAK-PARACURE
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/934,471 external-priority patent/US6693127B1/en
Priority claimed from US08/934,229 external-priority patent/US5902809A/en
Application filed by Individual filed Critical Individual
Publication of CA2287318A1 publication Critical patent/CA2287318A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002287318A 1997-04-26 1998-04-22 Pharmaceutical compositions of arglabin and arglabin derivatives Abandoned CA2287318A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
KZ9703971 1997-04-23
KZ970397 1997-04-26
US5168197P 1997-07-03 1997-07-03
US60/051,681 1997-07-03
US93422897A 1997-09-19 1997-09-19
US08/934,229 1997-09-19
US08/934,471 US6693127B1 (en) 1997-07-03 1997-09-19 Pharmaceutical compositions of arglabin and arglabin derivatives
US08/934,471 1997-09-19
US08/934,229 US5902809A (en) 1997-07-03 1997-09-19 Arglabin compounds and therapeutic uses thereof
US08/934,228 1997-09-19
PCT/US1998/007989 WO1998048789A1 (en) 1997-04-26 1998-04-22 Pharmaceutical compositions of arglabin and arglabin derivatives

Publications (1)

Publication Number Publication Date
CA2287318A1 true CA2287318A1 (en) 1998-11-05

Family

ID=27532391

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002287318A Abandoned CA2287318A1 (en) 1997-04-26 1998-04-22 Pharmaceutical compositions of arglabin and arglabin derivatives

Country Status (5)

Country Link
EP (1) EP0996441A4 (de)
JP (1) JP3507511B2 (de)
AU (1) AU7141898A (de)
CA (1) CA2287318A1 (de)
WO (1) WO1998048789A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994388A (en) 1997-03-18 1999-11-30 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
US6051565A (en) * 1997-04-26 2000-04-18 International Phytochemistry Research Labs, Ltd. Farnesyl-protein transferase inhibitors
GB9809889D0 (en) * 1998-05-11 1998-07-08 Univ Strathclyde Prevention of restenosis
WO1999064003A1 (en) * 1998-06-09 1999-12-16 Tovarischestvo S Ogranichennoi Otvetstvennostju 'tabifarm' Method of treatment of patients with initial liver cancer
CA2356438A1 (en) * 2001-09-05 2003-03-05 Andre Pichette Use of terpenes and derivatives as potentiators of antitumor agents in the treatment of cancers
US7678904B2 (en) 2003-07-11 2010-03-16 University Of Kentucky Use of parthenolide derivatives as antileukemic and cytotoxic agents
EP1643984B1 (de) * 2003-07-11 2011-07-06 University of Kentucky Research Foundation Verwendung von parthenolid-derivaten als antileukämische und zytotoxische mittel
CN102372723B (zh) * 2010-08-19 2014-03-26 石药集团中奇制药技术（石家庄）有限公司 一种从多花蒿中提取阿格拉宾的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663196A (en) * 1993-09-03 1997-09-02 Boston University Methods for treating neoplastic disorders

Also Published As

Publication number Publication date
EP0996441A4 (de) 2002-08-07
JP3507511B2 (ja) 2004-03-15
JP2002509532A (ja) 2002-03-26
WO1998048789A1 (en) 1998-11-05
EP0996441A1 (de) 2000-05-03
AU7141898A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
KR101869185B1 (ko) 혈액학적 장애의 치료에 사용하기 위한 glyt1 억제제
JP2007535525A (ja) β−カルボリン誘導体を含有する医薬組成物および癌を処置するためのそれらの使用
US8337903B2 (en) Antitumoral agents with a benzophenanthridine structure and formulations containing them
US5902809A (en) Arglabin compounds and therapeutic uses thereof
CA2287318A1 (en) Pharmaceutical compositions of arglabin and arglabin derivatives
JPH0720966B2 (ja) 製薬学的に活性な化合物を含有する病気治療剤
US6268394B1 (en) Farnesyl-protein transferase inhibitors
JPH09505579A (ja) イノシトール三燐酸エステルの薬剤調製への使用
US6693127B1 (en) Pharmaceutical compositions of arglabin and arglabin derivatives
US3852453A (en) Method of enhancing vincamine compositions
US6770673B1 (en) Therapeutic uses of arglabin in combination with other chemotherapy agents
EP0290817B1 (de) Anwendung von Oxetanocin zum Hemmen von HIV
CN110903289B (zh) 嘌呤-氨甲基-吡啶酮衍生物及其制备方法和用途
EP0476391B1 (de) Anti-AIDS-Zusammensetzung mit Cepharanthin als Wirkstoff
EP1611889A1 (de) Antibakterielles mittel und anti-krebs-mittel
KR20010020318A (ko) 아르글라빈 및 아르글라빈 유도체의 약학적 조성물
MXPA99009817A (es) Composiciones farmaceuticas de arglabina y derivados de arglabina.
US12129257B1 (en) Imidazo[1,2-a]pyrazine compounds as CK2 inhibitors
JPS63192717A (ja) 肝臓疾患用剤
KR20060066176A (ko) 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 신기능 치료제 조성물
KR101189692B1 (ko) 10-프로파르질-10-데아자아미노프테린을 사용하는 ｔ-세포림프종의 치료
EP0351173A2 (de) Substanz mit antiretroviraler Aktivität
JPS6129326B2 (de)
AU2004200434A1 (en) Farnesyl-Protein Transferase Inhibitors
JPH01228979A (ja) 新規ゲルマクラン誘導体及び制癌剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued